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Objective. The aim of this review is to analyze preclinical and clinical studies investigating the anxiety effects of Citrus aurantium
or Citrus sinensis essential oils (EOs). Design. The bibliographic research was made on the major scientific databases. Analysis
included only articles written in English and published on peer-reviewed scientific journals describing preclinical experiments
and clinical trials carried out to investigate the antianxiety effects of Citrus aurantium or Citrus sinensis EOs on anxiety disorders.
Clinical studies reporting the antianxiety effects of products containingCitrus aurantium orCitrus sinensisEOs in combinationwith
other active substances, including medicinal plants, were excluded. Nine clinical studies fulfilled the criteria adopted for analysis.
Results. Data show that Citrus aurantium or Citrus sinensis EOs produce anxiolytic effects both in preclinical experiments and in
different clinical conditions. Citrus aurantium EO aromatherapy reduced anxiety level in the great part of stress conditions studied
(subjects affected by chronic myeloid leukemia and preoperative patients) except for a sample of patients subjected to colonoscopy.
Exposition to Citrus sinensis EO in clinical studies shows to be positive in reducing anxiety level in patients waiting for dental
treatment as well as in healthy volunteers submitted to an anxiogenic situation. Conclusions. Overview of clinical trials conducted
with Citrus aurantium or Citrus sinensis on people with anxiety showed that inhalation or oral administration of Citrus aurantium
and inhalation of Citrus sinensis can exert beneficial effects on anxiety; however, because of incomplete accuracy in the reporting
of methodology, further more complete clinical studies are warranted.
1. Introduction
Citrus plants derived from the single genus Citrus are largely
interbreedable. Among the common names given to the
various members of the citrus family, orange often refers to
the most popular Citrus sinensis and Citrus aurantium [1].
Chemical composition ofCitrus plants is characterized by the
presence of several polyphenolic classes, including flavones,
flavanones, flavonols, flavans, and anthocyanins [2, 3].
Experimental evidences highlight their pharmacolog-
ical effects including antioxidant, cardioprotective, anti-
proliferative, anticancer, and hypolipidemic activities [4–8].
In folk medicine, products derived from the peel and/or
whole dried immature fruit of orange plants have been
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used to treat several health problems such as gastrointestinal
disturbances, respiratory disorders as agent for cough [9–12],
insomnia, stress disorders, epilepsy, and anxiety [12, 13].
Other citrus species such as Citrus bergamia have been
described for their effects against stress, psoriasis, and hyper-
lipidemia [14]. The present article focuses on antianxiety
preclinical and clinical effects of the twomost common citrus
species Citrus aurantium and Citrus sinensis.
Citrus aurantium L., also called Seville orange, sour
orange, or bitter orange, is a small citrus tree, about five
meters tall, with scented white flowers, belonging to Rutaceae
family, originating in eastern Africa, Arabia, and Syria, and
cultivated in Spain, Italy, and North America [1, 15].
Citrus aurantium is called with several local common
names in different countries where it is used for food,
fragrance, and medical application. Fruit, peel, leaves, flow-
ers, seeds, and essential oil (EO) of Citrus aurantium are
used in perfumes and cosmetics, as well as in the food
and confectionery industry [16]. Bitter orange oil, obtained
from the pressure of the fresh peels, is widely used as
a flavoring agent in the food industry and for beverages,
particularly liqueurs and soft drinks [17]. The composition
of the volatile oils is significantly different in flowers, leaves,
and peel. Linalyl acetate (50%) is the main constituent in
oil from the leaves (petit grain), and linalool (35%) in oil is
derived from the flowers (neroli) [18–20]. Flavones, alkaloids
such as synephrine and octopamine, carotenoids, and N-
methyltyramine are contained in peel, besides the volatile
oil. The main active ingredient in bitter orange extract is
the phenyl-ethylamine protoalkaloid p-synephrine which
represents about 90% or more of the total protoalkaloids.
Fruit peel contains a volatile oil composed of d-limonene,
d-linalool, N-acetyl octopamine, gamma-aminobutyric acid,
flavonoids, coumarins, triterpenes, vitamin C, carotene, and
pectin [21]. Other minor protoalkaloidal constituents in
Citrus aurantium octopamine, hordenine, tyramine, and
N-methyltyramine are absent or in trace amounts in bitter
orange extracts [22–25].
Standardized aqueous-alcoholic extracts of the immature
fruits of Citrus aurantium are widely consumed in dietary
supplements for appetite control, weight management, sports
performance, and energy, and bitter orange products are also
consumed in the form of food as juices and marmalades
[16, 26].
Citrus aurantium EO, also known as neroli oil, is widely
used in aromatherapy. It has been suggested that it stim-
ulates central nervous system, lowers blood pressure, and
has sedative, analgesic, anti-inflammatory, antispasmodic,
carminative, digestive, and diuretic effects [27]. It is a strongly
scented bitter liquid, produced by hydrodistillation of Citrus
aurantium fresh lives [28].
Citrus sinensis L., named orange or sweet orange, is a
millennial small tree belonging to theRutaceae (citrus) family
originated in southern China. The orange tree is small, spiny
tree, typically growing to 7.5 m, but occasionally reaching
heights up to 15 m, generally with a compact crown. Orange
tree grows in tropical, semitropical, and warm temperate
regions, becoming the most widely cultivated fruit tree in the
world [29, 30]. Orange is the world’smost popular fruit and is
eaten fresh or drunk as juice. Juice can be consumed directly
or further processed into concentrate, and both derivatives
are used in soda and cocktail drinks, punches, and liqueurs.
Orange fruits and peels are also used in desserts, jams and
marmalades, and candied peels, as well as cookies, cakes, and
candies. EO derived from orange peels, flowers, leaves, and
twigs is used in perfumes; orange seed oil may also be used in
cooking or as a component in plastic industry [30].
The sweet orange tree is found more or less in the same
places as the bitter orange tree. Sweet orange oil is extracted
from the fruit of the tree via cold pressure; it is also possible
to distill sweet orange oil [31].
Citrus sinensis contains several active secondary metabo-
lites contributing to the pharmacological activities of the
plant. In Citrus sinensis fruits, peel, leaves, juice, and roots,
several types of chemical compounds including flavonoids
[2, 32], hydroxyamides, steroids, alkanes and fatty acids,
coumarins, carbohydrates, peptides, carbamates and alky-
lamines, carotenoids, volatile compounds, and minerals such
as potassium, magnesium, calcium, and sodium have been
identified [12, 33].
C. sinensis is a rich source of vitamin C, a natural
antioxidant that support the immune system activity [33, 34].
C. sinensis has been used traditionally, to treat intestinal
disorders (such as cramps, constipation, colic, and diarrhea),
respiratory disorders (such as cough, cold, bronchitis, and
tuberculosis), obesity,menstrual disorder, cardiovascular dis-
ease (angina, hypertension), anxiety, depression, and stress
[35].
Anxiety disorders are among the leading prevalent causes
of global mental disorders [36, 37].They contribute to favour
poor compliance with therapy [38] and insufficient patient
adoption of healthy behaviors [39]. On the basis of their
negative effects on the results of therapy, it is necessary to find
effective interventions.
It is known that inhalation of volatile components of
Citrus EO is able to influence the activity of brain areas such
as the hypothalamus, hippocampus, and pyriform; preclinical
and clinical research showed that citrus fragrance can restore
stress-induced cortex [40, 41] and immunosuppression [42]
and may have potential antidepressant effects in rats [43, 44].
In light of the abovementioned findings, we tried to assess
if the potential health effects of both Citrus aurantium and
Citrus sinensis are really effective in the treatment of anxiety
conditions. With this aim, we summarized the published
reports of preclinical and clinical studies regarding the use
of Citrus aurantium- or Citrus sinensis-based products in
conditions related to anxiety disorders.
2. Methods
2.1. Research Method and Inclusion Criteria of Clinical Trials.
A bibliographic research was carried out independently
by two researchers (blinded to the authors and initially
on results) in the major scientific databases and search
engines of peer-reviewed literature from 2000 to July 2018,
on life sciences and biomedical topics (PubMed, Scopus,
Embase, Web of Science, and Google Scholar). The following
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Numbers of records identiﬁed through
database searching
n = 94
Number of additional records identiﬁed
through other sources
n = 0
Records aer duplicates removed
n = 84
Records excluded for title and abstract
n = 63
Records excluded aer full review
n = 4 (association products)
Full text articles assessed for
eligibility
n = 21
Articles included in the study n = 17
Pre-clinical studies n = 8
Clinical studies n = 9
Figure 1: PRISMA flowchart showing the process of literature search and studies selection.
keywords or combination of keywords “Citrus anxiety”,
“Citrus aurantium axiety”, “Citrus sinensis anxiety”, and
“clinical trials” were used. Analysis included only articles
written in English and published on peer-reviewed scientific
journals describing clinical trials and applications of Citrus
aurantium or Citrus sinensis EOs. Articles describing the
effects of products containing Citrus aurantium or Citrus
sinensis EOs in combination with other active substances
including medicinal plants derivatives were also excluded.
The selection and the review of clinical studies written in
English regarding Citrus aurantium or Citrus sinensis EOs
were performed in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement [45]. Methodological quality was assessed using
validated tools such as the Consort Statement in Reporting
Clinical Trials with Herbal Medicine Intervention (Section 4)
[46] and the Jadad Scale [47]. From the eligible articles,
two investigators independently extracted data by using a
standard data extraction form. Data were considered for
therapeutic indication, design of the study, number, sex, and
age of subjects, endpoints, adverse effects, and outcome. In
all the studies, reporting of adverse reactions was moni-
tored. The absence of adverse reactions was defined as “not
reported.” All the authors reviewed all the eligible articles
and resolved by discussion any uncertainty regarding the
statistical method used to handle the missing data.
3. Results
A collection of 94 scientific articles was selected from our
bibliography research. Only 17 articles describing effects of
Citrus aurantium or Citrus sinensis treatment for anxiety
were corresponding to the inclusion criteria. 63 articles
were excluded for title and abstract and 4 were excluded
because the products object of the studies were combinations
including Citrus aurantium.
Nine clinical studies were included in the review (Fig-
ure 1). In eight clinical studies, Citrus aurantium or Citrus
sinensis were administered for inhalation as aromatherapy,
and in one study Citrus aurantium was orally administered.
Table 1 summarizes for each preclinical study the authors,
the route of administration, animal species, experimental
model to study anxiety, dose, and observed effects of Citrus
aurantium or Citrus sinensis administration. Tables 2 and 3
summarize authorship of the paper, therapeutic indication,
study design, subjects involved, endpoints, adverse effects,
and outcome of all the clinical trials regarding use of Citrus
aurantium or Citrus sinensis, respectively. Tables 4 and 5
report CONSORT items for trials with herbal medicine
interventions applied to clinical studies, for Citrus aurantium
and Citrus sinensis, respectively. Table 6 reports quality
assessment of randomized controlled trials by the Jadad
scoring system.
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Table 4: Section 4 of elaborations of CONSORT items for trials with herbal medicine interventions applied to clinical studies with Citrus
aurantium herbal preparations.
Reference
Herbal medicinal
product name Characteristics ofthe herbal product
Dosage, regimen and
quantitative
description
Qualitative
testing
Placebo/control
group (rationale
for control or
placebo used)
Practitioner
Latin
name
Brand
name Dose
Duration
of use
Chaves Neto
et al., 2017 Yes Yes Yes Yes Yes Yes Yes Yes
Fernandes
Pimenta et
al., 2016
Yes Yes Yes Yes Yes Yes Yes Yes
Namazi et al.,
2014 Yes Yes No Yes Yes No Yes Yes
Hu et al., 2010 No No No Yes Yes No Yes Yes
Hasheminia
et al., 2014 Yes No No Yes Yes No Yes Yes
Akhlaghi et
al., 2011 Yes Yes Yes Yes Yes Yes Yes Yes
Table 5: Section 4 of elaborations of CONSORT items for trials with herbal medicine interventions applied to clinical studies with
Citrussinensis herbal preparations.
Reference
Herbal medicinal
product name Characteristics ofthe herbal product
Dosage, regimen and
quantitative
description
Qualitative
testing
Placebo/control
group (rationale
for control or
placebo used)
Practitioner
Latin
name
Brand
name Dose
Duration
of use
Jaafarzadeh et
al., 2017 Yes Yes Yes Yes Yes Yes Yes Yes
Costa Goes et
al., 2012 Yes No Yes Yes Yes Yes Yes Yes
Lehrner et al.,
2000 Yes Yes Yes Yes Yes Yes Yes Yes
3.1. Citrus aurantium (Sour/Bitter Orange) Preclinical and
Clinical Antianxiety Effects. Antianxiety effects of Citrus
aurantium were demonstrated through behavioral experi-
ments carried out with laboratory animals. C. aurantium EO
oral administration inmice increased exploration of the open
arms (time spent) in the elevated plus-maze at a dose that
did not impair motor activity observed with open-field and
rotarod test, which is indicative of anxiolytic-like effect in
male mice [48].
The acute administration induced an anxiolytic-like effect
in the light/dark transition tests (increased time spent in the
light side, and in the number of transitions) and in marble
burying (decreased number of marbles buried) without any
motor impairment, while repeated administration showed
effects in the marble-burying test only. Repeated diazepam
administrations did not increase light/dark transitions. Thus,
the results suggest an anxiolytic-like effect following acute
and repeated Citrus aurantium EO administration [49].
Similar results were obtained in another experiment
showing that anxiolytic-like effect of oral administration of
Citrus aurantium EO was reversed by 5-HT1A antagonist
WAY100635 but not by flumazenil, a benzodiazepine antag-
onist, suggesting serotonergic mediation [44].
In another study, inhalation of Citrus aurantium EO
increased social interactions (time spent in active social inter-
action) in rats and increased exploration time in the open
arms of the elevated plus-maze, suggesting an anxiolytic-like
effect at a dose that did not impair motor activity in the open-
field test [50].
Acute intraperitoneal administration of Citrus aurantium
EO, similar to fluoxetine, increased open arm explorations
(percentage of time spent and percentage of entries) in the
elevated plus-maze in male mice. The authors suggested that
the effect of Citrus aurantium L. is linked to serotonergic
transmission based on a fluoxetine + Citrus aurantium EO
interaction. However, Citrus aurantium EO did not change
the anxiolytic effect of fluoxetine in the elevated plus-maze,
suggesting no drug interaction [51].
Khosrovi et al. investigated the effect of intraperi-
toneal injection of Citrus aurantium EO on anxiety and
its interaction with GABAergic pathways, evaluating the
coadministration effects of Citrus aurantium and diazepam.
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Table 6: Clinical trials quality assessment according to Jadad score.
Authors
Was the trial
described as
randomized?
Was the
randomization
procedure
described and
appropriate?
Was the trial
described as
double-blind?
Was the method
of double
blinding
described and
appropriate?
Was the
number of
withdrawals/dropouts
in each group
mentioned?
Jadad
Score
Citrus aurantium
Fernandes
Pimenta et al.,
2016
Yes Yes No No No 2
Chaves Neto et
al., 2017 Yes No No No No 1
Namazi et al.,
2014 Yes Yes No No Yes 3
Pei-Hsin et al.,
2010 Yes No No No No 0
Hasheminia et
al., 2014 Yes Yes No No No 2
Akhlaghi et al.,
2011 Yes Yes Yes Yes Yes 5
Citrus sinensis
Lehrner et al.,
2000 Yes No No No No 0
Jaafarzadeh et
al., 2017 Yes Yes Yes No Yes 3
Costa Goes et
al., 2012 Yes Yes Yes No Yes 3
The JADAD scoring system was used for the assessment of randomized controlled trials with the following 5 items:
Was the study described as randomized? (Yes = 1 point, No = 0 points);
Was the randomization scheme described and appropriate? (Yes = 1 point, No = -1 point);
Was the study described as double-blind? (Yes = 1 point, No = 0 points);
Was the method of double blinding appropriate? (Yes = 1 point, No = -1 point. If the answer of Item 3 was No, Item 4 is not calculable);
Was there a description of dropouts and withdrawals? (Yes = 1 point, No = 0 points).
Results showed that Citrus aurantium EO increased the
open arms exploration (increase of percentage time spent)
of male mice submitted to the elevated plus-maze. Although
diazepam increased open arms exploration (percentage of
time spent and percentage of entries), coadministration with
Citrus aurantium reduced the anxiolytic effect of diazepam.
Flumazenil did not alter the effect of Citrus aurantium;
however, authors suggest that Citrus aurantium L. may exert
an anxiolytic-like effect acting as partial agonist at the GABA-
A receptor/benzodiazepine site [52]. Preclinical antianxiety
effects of Citrus aurantium are summarized in Table 1.
Complex six studies investigating Citrus aurantium EO
effects on anxiety levels during different medical conditions
were found. All of the six studies in which Citrus aurantium
was investigated were randomized/controlled clinical trials.
One randomized clinical trial described the effects of
Citrus aurantium EO in reducing anxiety during labor in a
group of Iranian pregnant women [53].
Before the aromatherapy, both groups had the same levels
of anxiety; the levels of anxiety evaluated at dilations of 3-
4 and 6-8 cm were significantly lower in the aromatherapy
group with Citrus aurantium compared with the control
group, thus suggesting that aromatherapy with Citrus auran-
tium EO could reduce anxiety during labor [53].
A trial was carried out on patients proposed for
colonoscopy and divided into two groups. Aromatherapy was
performed by inhalation of Sunflower oil (control group)
and Neroli oil (experimental group). Results showed that
there was no significance difference of procedural anxiety
measured by State Trait Anxiety Inventory state (STAI-S)
score and procedural pain evaluated by visual analogue scale
(VAS), before and after aromatherapy in patients subjected to
colonoscopy. Significant lower pre- and postprocedural sys-
tolic blood pressure in Neroli group than control group were
observed.The authors concluded that the inhalation aromatic
agent had an effect on lowering procedural anxiety-related
(excessive fear of medical, dental, or surgical procedures that
results in acute distress or interference) blood pressure [54].
Patients with a mandibular third molar with B II classi-
fication of impacted teeth and American Society of Anaes-
thesiologists (ASA) class I patients (healthy subjects with
no organic pathology), with moderate and high anxiety
levels measured through the dental anxiety scale (DAS)
questionnaire, were included in another randomized and
controlled study.
The ASA clinical status classification system assessed
the fitness of patients before surgery. The outcome variables
were physiologic measures related to anxiety, including mean
blood pressure, respiratory rate, and pulse rate.
After aromatherapy, mean blood pressure, pulse rate,
and respiratory rate were significantly lower in the fragrance
group during surgery (from the time of sitting in the dental
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chair to the end of surgery). Vital signsmeasurements showed
significant differences between the two groups, which may
be due to the sedative effect of the orange fragrance during
surgery. Results suggest that ambient orange fragrance could
be helpful in reducing dental anxiety during dental surgical
removal [55].
Another study was carried out on a Brazilian volunteers'
cohort with chronic myeloid leukemia (CML), treated with
standard therapy. The study compared Citrus aurantium
EO with diazepam anxiolytic effects, in the moment that
precedes the collection of medullary material in patients
with CML. Systolic and diastolic blood pressure and cardiac
and respiratory frequencies were measured. C. aurantium
EO decreased both systolic and diastolic blood pressure
while with diazepam, only systolic blood pressure decreased.
The Citrus aurantium EO did not decrease the respiratory
frequencies.
The use of STAI-S revealed an anxiolytic effect of Citrus
aurantium EO group of patients with CML but not in the
CML diazepam and placebo groups. In conclusion, study
results showed an anxiolytic effect of Citrus aurantium EO
in patients with CML with an improvement of psychological
and physiologic parameters. For the authors, this effect has
a great clinical relevance, because patients with cancer go
through various stressful phases during the disease, and
the standard therapy significantly contributes to improve
the anxiety level and physiological parameters during a
procedure that is a cause of distress [13].
Chaves Neto et al. (2017) studied the anxiolytic effects
of Citrus aurantium EO in patients experiencing crack with-
drawal. Based on the fact that individuals who experience
crack withdrawal present a high anxiety trait, anxiety status
was induced with the Simulated Public Speaking (SPS)
method (subject is requested to deliver a speech in front of a
video camera with its image being displayed on a TV screen).
Anxiety levels were assessed by the Inventa´rio de Ansiedade
Trac¸o-Estado (IDATE), the Brazilian version of STAI-S.
The results demonstrated that subjects in the groups
treated with Citrus aurantium EO maintained controlled
anxiety levels during SPS when compared to the control
group (no treatment). Subjects whowere administered Citrus
aurantium EO also maintained states of discomfort and
cognitive impairment often associated with anxiety during
SPS. However, nebulization of the EO of Citrus aurantium
provided an acute anxiolytic effect in crack cocaine users
exposed to SPS.
Authors’ conclusions were that Citrus aurantium EO,
administered by nebulization, produced anxiolytic effects in
crack users in abstinence thus indicating the possibility of
Citrus aurantium EO use as an alternative complementary
therapy in the control of anxiety in users who are abandoning
drugs abuse [56].
In a randomized double-blind design, the effect of
oral administration of Citrus aurantium blossom distillate
(CABd) on preoperative anxiety was evaluated. Preoperative
anxiety was assessed using STAIS and Amsterdam Preop-
erative Anxiety and Information Scale (APAIS). The main
finding of this study was the confirmation of the anxiolytic
effect obtained with oral administration of blossom distillate
Citrus aurantium. Both STAI-state and APAIS scores were
decreased by CABd. On the other hand, neither STAI-state
nor APAIS was changed in the placebo group [57].
Results of the studies using Citrus aurantium EO showed
that inhalation of the oil produces significant anxiolytic
effects. Methods for diffusion of EO used in the studies are
by direct inhalation with hand-hold nebulizers generally with
doses of EO ranging 10 – 50 mL or by dilution of EO in
distilled water and successive diffusion through an electric
dispenser or by gauzes impregnated with 4 mL of Citrus
aurantium EO.
3.2. Citrus sinensis (Sweet Orange) Pre-Clinical and Clinical
Anti-Anxiety Effects. In comparison to findings published
about investigation on Citrus aurantium, a reduced number
of preclinical and clinical experiments were conducted on
Citrus sinensis. Inhalation ofCitrus sinensisEO (sweet orange,
containing 97% limonene) in rats submitted to elevated
plus-maze followed by the light/dark paradigm produced
an increase in open arm exploration (% time spent and %
number of entries) in the elevated plus-maze, and of the time
spent in the lit chamber of the light/dark test. No effect on
motor activity, as measured by the total distance travelled in
the elevated plus-maze, was detected [58].
Anxiolytic-like, sedative, and antidepressant-like poten-
tial effects of inhalation of both Citrus aurantium and Citrus
sinensis EOs were evaluated through behavioral tests and
measurement of corticosterone and melatonin plasma levels
in mice.
Results of behavioural tests showed an anxiolytic-like
and sedative effect of Citrus sinensis EO 10% inhalation,
without affecting melatonin and corticosterone physiological
levels. Inhalation of 10% Citrus aurantium EO did not show
neither anxiolytic-like effects nor change in melatonin and
corticosterone plasma levels [59].
Three randomized and controlled studies investigating on
the effects of Citrus sinensiswere found. Two studies describe
the effects of Citrus sinensis EO on anxiety in adults and
children, respectively, subjected to dental treatments.
A randomized controlled trial was carried out on adult
patients waiting for dental treatment to evaluate the anx-
iolytic effects of Citrus sinensis. Orange odor was diffused
in the waiting room of odor group through an electrical
dispenser whereas in the control group no odor was diffused.
For assessing cognitive functions, patients completed the
Wortschatz test (WST) [60]. For assessing trait and state
anxiety, patients were given the State-Trait Anxiety Inventory
(STAI) [61]. The Mehrdimensionale Befindlichkeitsfragebo-
gen (MDBF) [62] were used for assessment of current mood,
alertness, and calmness.
Results of the study showed that exposure to ambient
orange odor has a relaxant effect compared to control group.
Results reported also a sex difference ofCitrus sinensis effects,
showing that women exposed to sweet orange EO had a lower
level of state anxiety, amore positive mood, and a higher level
of calmness [63].
The effects of orange odor (Citrus sinensis) on child anx-
iety during dental treatment were also evaluated in another
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study by using salivary cortisol and pulse rate as index of
patients' anxiety.
The results of this study showed that the salivary cortisol
level and pulse rate significantly decreased in intervention
groups by using aromatherapy with Citrus sinensis EO [64].
The potential anxiolytic effect of Citrus sinensis EO was
evaluated in a double-blind, randomized, placebo-controlled
clinical trials carried out on healthy volunteers submitted to
an anxiogenic situation. Immediately after inhalation, each
subject was submitted to the video-monitored version of
the Stroop Color-Word Test (SCWT), a method to induce
anxiety. During the text, a board with 100 of the color-naming
words blue, yellow, red, green, and violet organized randomly
in a 10 ⋅ 10 matrix is presented to each participant. The color
of each word is different from its own meaning (for example,
the word “green” printed in red). The participant has to say
quickly (in two minutes) the sequence presented, the color
of the ink, but not the colors described by the single words.
The whole test is recorded and presented to the subject on a
monitor during the test [65].
State-Trait Anxiety Inventory (STAI) and Visual Ana-
logueMood Scale (VAMS) were used to evaluate psychologic
parameters. Physiologic parameters were evaluated before
the inhalation period and before, during, and after the
SCWT. Results showed dose-dependent anxiolytic properties
of sweet orange EO [65].
These three studies indicate that Citrus sinensis EO exerts
anxiolytic effects in anxiogenic situations. One of the studies
show that Citrus sinensis EO exerts its anxiolytic effects also
in children.
4. Discussion
EOs physiological and psychological effects are known in
folk medicine and aromatherapy for a long time [14, 66].
Aromatherapists have proposed that Citrus fragrances have
mood-enhancing properties.These effects were confirmed by
successful clinical study carried out with citrus fruits oils on
patients affected by stress symptoms or depression [67, 68].
Anxiety disorders are the most common type of psychi-
atric disorders in the general population [69].Their treatment
is difficult because of the important side effects of the drugs
used to improve anxiety symptoms, which generally promote
dependence [70].Moreover, common treatments do not ben-
efit all patients and only few of them have a slight resumption
[71]. These conditions justify the increasing interest and
search for alternative or complementary procedures aimed at
improving anxiety symptoms. One of these is aromatherapy,
a procedure that uses EOs by inhalation as a treatment for
medical purposes [72].
Citrus aurantium and Citrus sinensis are rich in flavonoids
and polyphenolic compounds with numerous pharmacolog-
ical properties, such as the inhibition of the oxidation of low-
molecular weight proteins and platelet accumulation thus
contributing to immune cell stability.
They are also used in treatment of mental disor-
ders, inflammation, viral infections, and allergies [73, 74].
Flavonoids effects in reducing anxiety are due to their action
as benzodiazepine receptor agonists [57].
A series of review articles regarding the safety and efficacy
of bitter orange has been published [75–78]. However, this is
the first analysis of clinical studies using Citrus aurantium or
Citrus sinensis for the treatment of anxiety. We analyzed all
clinical studies according to the recommendations described
in the checklist developed by the Consolidated Standards of
Reporting Trials [46] for the reporting of clinical trials using
herbal medicinal products (Tables 4 and 5).The clinical trials
included in this reviewhave different levels ofmethodological
accuracy. All of studies were randomized and controlled.
Only one study regarding Citrus aurantium use was carried
out with a double-blind methodology (Table 2). Two of the
studies regarding Citrus sinensis use were carried out with a
double-blind methodology, and only one was performed as a
crossover study (Table 3).
Since it is a common source of selection bias, a point of
weakness in all the studies is the lack of description of the
methods adopted to generate random allocation sequences
[78] (Table 6). Moreover, all the studies were poor in number
of subjects recruited. In four of them, the sample of people
recruited did not exceed 50 patients, in four studies, the
samples exceeded 50 participants, and only in one study the
sample was more than 100 patients (Tables 2 and 3).
All the studies reported statistical data analysis but no one
reported sample size calculation. Latin binomial name of the
plant was always correctly reported, although not all articles
provided an exhaustive description of the characteristics
of the product. Procedure adopted to obtain the EO and
description of the raw material used to produce the herbal
preparations were reported only in one study (Tables 4 and
5). The highest standards in methodology for clinical trials
in herbal medicine strongly recommend the reporting of the
characteristics of the product to facilitate the reproducibility
of the studies. The presence of these data are fundamental to
establish a link between the putative efficacy and safety to the
single product [46].
Only few studies report qualitative testing producing the
chemical fingerprint of the herbal products (Table 4). Finally,
one study [13] compares the effects of Citrus aurantium
against diazepam, a well-established drug prescribed for the
treatment of anxiety (Table 2).
5. Conclusions
Antianxiety effects of Citrus aurantium and Citrus sinen-
sis EOs were previously demonstrated through behavioral
experiments carried out on laboratory animals. Complex
clinical studies considered for this overview suggest that
Citrus aurantium or Citrus sinensis EOs, used for anxi-
olytic therapy of people prevalently in conditions in which
stress is dominating, produce positive effects against anxiety.
In particular, Citrus aurantium EO aromatherapy reduced
anxiety level in the great part of stress conditions studied
(subjects affected by chronic myeloid leukemia and preop-
erative patients) except for a sample of patients subjected
to colonoscopy. Exposition to Citrus sinensis EO in clinical
studies is shown to be positive in reducing anxiety level in
patients waiting for dental treatment as well as in healthy
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volunteers submitted to an anxiogenic situation. However,
a definitive conclusion needs further studies because of the
reduced number of studies and the small number of patients
for each study. Regarding data reporting of clinical studies
with Citrus aurantium, they appear without description of
the characteristics of the herbal product and lack qualitative
testing. From the methodological point of view, most of the
clinical studies show the lack of important items such as
treatment allocation conceal and description of double-blind
procedure. On the basis of the present overview, we can
conclude that the use of Citrus aurantium and Citrus sinensis
EOs could be useful to reduce anxiety caused by clinical
stress conditions; however, results are impaired by the poor
accuracy and methodology applied in clinical studies.
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